[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 27, 1999

Time for Action on Drug Safety

Author Affiliations
 

Margaret A.Winker, MDIndividualAuthorPhil B.FontanarosaMD, Senior EditorsIndividualAuthor

JAMA. 1999;281(4):319-322. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-4-jbk0127

To the Editor: The Commentary by Mr Moore and colleagues1 on the need for better postmarketing drug surveillance raises important issues. We agree with the need for a "more active and effective safety program for marketed drugs." With an estimated 2 million hospital patients experiencing serious adverse drug reactions (ADRs) and 100,000 having fatal ADRs in 1994,2 and with increasing numbers of new drug approvals, the ability of the government to protect the public health is increasingly challenged. This is particularly salient since approximately 48% of the currently available prescribed drugs came on the market after 1990 with an accelerating rate of new drug approvals.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×